Grimbly, C. http://orcid.org/0000-0002-9302-7741
Escagedo, P. Diaz http://orcid.org/0000-0001-6469-3510
Jaremko, J. L.
Bruce, A. http://orcid.org/0000-0001-5754-017X
Alos, N. http://orcid.org/0000-0003-1258-7665
Robinson, M. E. http://orcid.org/0000-0002-2539-227X
Konji, V. N.
Page, M.
Scharke, M.
Simpson, E. http://orcid.org/0000-0002-6052-5904
Pastore, Y. D.
Girgis, R.
Alexander, R. T. http://orcid.org/0000-0001-7396-7894
Ward, L. M.
Article History
Received: 13 January 2022
Accepted: 28 May 2022
First Online: 29 July 2022
Declarations
:
: The study was approved by the University of Alberta, CHEO, and CHU St. Justine Research Ethics boards. The study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: CG has been a consultant to Ultragenyx and IPSEN. LMW has been a consultant to, and participated in clinical trials with, Ultragenyx, Novartis, and Amgen (with funds to Dr. Ward’s institution). NA has participated in clinical trials with Novartis, Amgen, Europharm, and Levo therapeutics. MER has been a consultant to Ultragenyx and IPSEN and has received a research grant from Ascendis Biopharma. YDP has been a consultant to and participated in clinical trials with Novartis, Agios, Forma Pharmaceutic, and Principia. RG has been a consultant to IPSEN and Pfizer and has received research grants from Novo-Nordisk and Ascendis. PDE, JLJ, AB, VNK, MP, MS, and ES declare that they have no conflict of interest.